NCT00056095 is a Phase 2 clinical trial of therapeutic allogeneic lymphocytes in Kidney Cancer, sponsored by UNICANCER.

Who is sponsoring NCT00056095?

NCT00056095 is sponsored by UNICANCER.

What drugs are being tested in NCT00056095?

Interventions in NCT00056095: therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation.

What condition does NCT00056095 study?

NCT00056095 studies Kidney Cancer.

Is NCT00056095 still recruiting?

NCT00056095 is currently completed. Last updated 24 February 2021.

Last reviewed 2021-02-24 · How we verify

NCT00056095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Completed Phase 2 Last updated 24 February 2021

What this trial tests

Phase 2 trial testing therapeutic allogeneic lymphocytes in Kidney Cancer in 57 participants. Completed in 17 August 2016.

Timeline

4 November 2002

Primary endpoint
13 February 2008

17 August 2016

Quick facts

Lead sponsor	UNICANCER
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	4 November 2002
Primary completion	13 February 2008
Estimated completion	17 August 2016
Sites	26 locations across France

Drugs / interventions tested

therapeutic allogeneic lymphocytes — full drug profile →
cyclophosphamide (cyclophosphamide) — full drug profile →
cyclosporine (cyclosporine) — full drug profile →
fludarabine phosphate (FLUDARABINE PHOSPHATE) — full drug profile →
allogeneic bone marrow transplantation
peripheral blood stem cell transplantation

Conditions studied

Kidney Cancer — all drugs for Kidney Cancer →

Sponsor

UNICANCER — full company profile →

Who can join

Adults 18 to 65, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well allogeneic stem cell transplant works in treating patients with metastatic kidney cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.
Tykodi SS, Sandmaier BM, Warren EH, Thompson JA. · · 2011 · cited 4× · PMID 21417772 · DOI 10.1517/14712598.2011.566855

Verify or expand the search:

Other trials of therapeutic allogeneic lymphocytes

Trials testing the same drug.

NCT00448201 — Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant · Phase 2 · completed
NCT00043979 — Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas · Phase 2 · completed
NCT00053989 — NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders · Phase 2 · completed
NCT00033475 — Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative · Phase 3 · completed
NCT00004878 — Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia · Phase 2 · withdrawn

Other recruiting trials for Kidney Cancer

Currently open trials in the same condition.

NCT07401875 — A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · Phase 1 · recruiting
NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting

Other UNICANCER trials

Trials by the same sponsor.

NCT07340619 — Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT07360834 — Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndr · NA · not yet recruiting
NCT07106632 — Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests · Phase 3 · not yet recruiting
NCT07294430 — Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate. · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00056095 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNICANCER
Last refreshed: 24 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00056095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing